Quality policy

ACCESS PHARMA S.A. ensures the continuous satisfaction of its customers' requirements and considers the management of all the processes that constitute its operation as the main factor of primary importance. For this reason, the company has been developing, installing and implementing an integrated Quality Management System, in accordance with ISO 9001: 2015 standard, while adhering to the Guidelines (2013/C 343/01) on Good Distribution Practice of medicinal products for human use and medical devices. ACCESS PHARMA S.A. is consistently delivering quality services, and is committed to the continuous improvement of both the system itself and the operating processes and services provided.

As part of its highly recorded and implemented policy, the company monitors and tracks customer needs, as well as developments in technology and the market in which it operates, as well as up-to-date services to ensure that its customers' requirements and expectations are fully met.

For ACCESS PHARMA S.A. the concept of quality consists of the following:

  • Providing services that focus on safeguarding interests and meeting customer needs and expectations.
  • Accurate and continuous quality control of the company's operating processes at each discrete stage.
  • Commercial policy to maintain competitive prices at both direct market costs and long-term economic benefits.
  • Rapid response to service delivery and product delivery.
  • Honesty, clarity and reliability in communicating and working with customers.
  • Compliance with laws and regulations.


Phone: +30 2310461600 
Fax: +30 2310463500
Address: 14th km Thessalonikis-N. Moudanion, Thermi,
57001, PO Box 60767
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Find us on
linkedin icon white



Copyright © 2020 ACCESS PHARMA SA | Terms of Use 
powered by NICMEDIA

This webpage has been produced with the financial assistance of the European Union. The contents of the webpage are sole responsibility of access pharma sa and can in no way be taken to reflect the views of the European Union, the participating countries the Managing Authority and the Joint Secretariat